2005 Jan;194(1-2):55-9
Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials in adults, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%)
Preparing small, single-use aliquots can reduce repeated freeze-thaw exposure, but the acceptable storage period still needs experimental support
The Globe is looking to talk to Massachusetts residents who were taking GLP-1 drugs to lose weight and are now facing challenges getting their insurers to cover the medication
This direction will help determine safety, optimal dosing, and efficacy and capture any potential side effects and safety signals through comprehensive toxicological studies
Both produce a clear, injectable solution